Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
Official title: A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo
Status: Opening soon
Description:
The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo. The main question this clinical trial aims to answer is: • Can ACT-777991 help return color to the skin of the face of adults with non-segmental vitiligo? Researchers will compare ACT-777991 to placebo (a look-alike inactive treatment that contains no medicine) to see if ACT-777991 works to treat non-segmental vitiligo. Trial participants will: • Take the trial intervention (either ACT-777991 or placebo) daily for 24 weeks. • Visit the clinic 7 times for check-up and tests.
Phase: Phase 2.
What is being studied: drugs — ACT-777991, Placebo.
Who can take part: ages 18 Years to 65 Years, 30 participants planned.
Enrollment status: Opening soon. The study started 01 June 2026 and is expected to finish 01 July 2027.
Contact: Clinical Trial Information USA.
Source: ClinicalTrials.gov, NCT07667569 (https://clinicaltrials.gov/study/NCT07667569).
Start date: June 01, 2026
Completion date: July 01, 2027
Organizer: Idorsia Pharmaceuticals Ltd.
Contact: Clinical Trial Information USA
Tel.: +1 856 661 37 21
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- What are risks of oral and topical corticosteroids?
Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Do Antioxidant Supplements Help Vitiligo?
Do Antioxidant Supplements Help Vitiligo? Short answer Maybe a little. But probably not in the way most people hope. Antioxidant supplements may offer modest support, especially...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.